Your mission The Josep Carreras Leukemia Research Institute (IJC) is a comprehensive cancer research center dedicated to researching and promoting innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukemia and other hematological malignancies, with the objective of finding a cure for these diseases.
It was created in 2010 and has experienced exponential growth since then.
The IJC is part of the network of Research Centers of Excellence of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation and Universities in 2024.
Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC).
The IJC is integrated into the accreditation of the Germans Trias i Pujol Research Institute (IGTP) as an Accredited Health Research Institute (IIS) by the Health Institute Charles III (ISCIII).
The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services.
The IJC has six headquarters integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar, and Hospital San Joan de Déu.
This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice.
We are seeking a LABORATORY TECHNICIAN for our institute.
RESEARCH DESCRIPTION The main goal of the Stem Cell Biology, Developmental Leukemia, and Immunotherapy group, led by Dr. Pablo Menéndez, is to investigate and understand the pathogenic mechanisms and cell-of-origin of pediatric leukemias and to develop novel adoptive immunocellular therapies based on the use of CAR T-cells.
Our group is interested in understanding the cellular origin, etiology, and pathogenesis of childhood leukemia.
We aim to ascertain the cell in which mutations occur and strive to discover which cells are responsible for triggering relapses.
Furthermore, we work to identify new therapeutic targets and develop more targeted, less toxic therapies.
To achieve this, our laboratory uses various approaches, including genetic studies, epigenetic techniques, animal models, and adoptive cell immunotherapy tools.
This contract is linked to the project PRYGN234975MENE, Next generation, off-the-shelf, CD1a/CCR9-directed dual CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia.
MAIN RESPONSIBILITIES Mouse colony management and breeding of immunodeficient colony (including NSG and NSGS strains).
Co-design, in close collaboration and communication with the researchers of the group, in vivo experimental procedures and experiments.
#J-18808-Ljbffr